Table 7 Characteristics of cases of serious skin disorders with past exposure to oral antifungals
From: Risk of serious skin disorders among users of oral antifungals: a population-based study
Past use | Age | Sex | Duration of treatment (days) | Days from last dose intake to initial symptoms | Dose (mg) | Diagnosis | Source of diagnosis | Current use with drugs potentially related with serious skin disorders |
|---|---|---|---|---|---|---|---|---|
Fluconazole | 57 | F | 1 | 43 | 150 | Erythema multiforme | Dermatologist | Cefaclor |
Fluconazole | 37 | F | 1 | 55 | 150 | Angioedema | GP | None |
Terbinafine | 76 | M | 196 | 16 | 250 | Angioedema | Dermatologist | Claritromicine |
Terbinafine | 46 | F | 28 | 63 | 250 | Angioedema | GP | None |
Terbinafine | 47 | F | 28 | 77 | 250 | Erythema multiforme | GP | Flucoxacilline |
Terbinafine | 48 | M | 14 | 28 | 250 | Erythema multiforme | GP | None |